7Clinical and laboratory standards institute performance standards for antimicrobial susceptibility testing fifteenth informational supplement[S].2005(M100-S15):52-55.
4Gem mell CG. Susceptibility of a variety of clinical isolates to linezolid:a European inter-country comparison [J]. J Antimicrob Chemother, 2001,48(1):47-52.
5CLSI(M100-S19)文件.2009.
6David FM, Arthur EB, Gary JN, et al. An investigation of vancomycin-resistant enterocicci faecium within the pediatric service of a large urban medical center[J]. Pediatr Infect Dis J, 1998,17(3):184.
7Cercenado E, Garcia-Garrote F, Bouza E. In vitro activity of linezolid agaist multiply resistant Gram-positive clinical isolates[J]. J Antimicrob Chemother, 2001,47(1):77-81.
8Ross JE, Fritsche TR, Sader HS, et al.Oxazolidinone susceptibility patters for 2005:Internation Report from the Zyvox Annual Appraisal of Potency and Spectrum Study [J ]. Int J Antimicrob Agents, 2007,29(3):295-301.
9Malik RK, Marisa AM, Mario RR, et al. Epidemiology and control of Vancomycin-resistant Enterococci in a regional neonatal intensive care unit[J]. Pediatr lnfect Dis J, 1999,18(4):352.
10Elsner HA, Sobottka I, Feucht HH, et al. In vivo susceptibilities of enterococccal blood culture isolates from the Hamberg area to ten antibiotics[J]. Chemotherapy, 2000,46:104-110.
